Law & Policy

·

Review

Hiding Dose Details Could Reduce Bias in Psychedelic Trials

Hiding Dose Details Could Reduce Bias in Psychedelic Trials

What they found

Researchers explored altering informed consent to reduce participants guessing their treatment in psychedelic trials.

Researchers explored altering informed consent to reduce participants guessing their treatment in psychedelic trials.

How solid is it?

Early human

Early human

Evidence ladder: Lab dish → Animal → Early human → Strong human. Reviews summarize earlier research.

At a glance

Latin name

Compound

psychedelics

psychedelics

Published in

JAMA Network

JAMA Network

Covered in Shroom Scan

Section

PSILOCYBIN & LEGISLATION

PSILOCYBIN & LEGISLATION

As it ran in Shroom Scan

Improving Psychedelic Research

Improving Psychedelic Research

To make clinical trials more reliable, researchers explored altering informed consent by hiding details like dosages and placebo chances. This reduces bias caused by participants guessing whether they received a psychedelic. While this approach could reveal more accurate treatment effects, it does raise ethical concerns about transparency.

To make clinical trials more reliable, researchers explored altering informed consent by hiding details like dosages and placebo chances. This reduces bias caused by participants guessing whether they received a psychedelic. While this approach could reveal more accurate treatment effects, it does raise ethical concerns about transparency.

Inflammation Relief, Microdosing Tips, and Fungi Fighting Pathogens

Read the original study ↗

Get Shroom Scan

Next study

Columbia Launches First In-Degree Psychedelic Therapy Program ›

Shroom Scan · Every Friday

Get Studies Like This, Translated, Every Week

Ten new studies a week, each boiled down to what it found and why it matters to you. Free, and one click to leave.

See what's inside →